How did BOT eff up? they submitted the pamphlet to the FDA for review during labeling discussions... only for the FDA to then find issues when doing the final review.
All the information the FDA wanted is already there, but the FDA want it on the box as well, and they want the pamphlet to fold a different way.
This is equivalent to knocking a drug back because of a single type.
- Forums
- ASX - By Stock
- BOT
- webinar
webinar, page-26
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $671.1M |
Open | High | Low | Value | Volume |
38.0¢ | 38.0¢ | 37.0¢ | $1.949M | 5.207M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 163455 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 33207 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 130837 | 0.370 |
10 | 99517 | 0.365 |
16 | 271384 | 0.360 |
7 | 220353 | 0.355 |
26 | 1051912 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 44778 | 1 |
0.385 | 245000 | 3 |
0.390 | 10960 | 1 |
0.395 | 123443 | 3 |
0.400 | 179748 | 4 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
BOT (ASX) Chart |